Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0004 0.00 (0.00%)
As of 05/22/2026 10:13 AM Eastern
Compare

SCPS vs. VINC, ADTX, VAXX, ELOX, and ORGS

Should you buy Scopus BioPharma stock or one of its competitors? MarketBeat compares Scopus BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scopus BioPharma include Vincerx Pharma (VINC), Aditxt (ADTX), Vaxxinity (VAXX), Eloxx Pharmaceuticals (ELOX), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

44.0% of Vincerx Pharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

Summary

Vincerx Pharma and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Aditxt?

Scopus BioPharma (NASDAQ:SCPS) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Aditxt -360,152.50%-839.49%-105.93%

In the previous week, Aditxt had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 1.00 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company Overall Sentiment
Scopus BioPharma Neutral
Aditxt Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
AditxtN/AN/A-$41.71M-$11.10 thousandN/A

15.5% of Aditxt shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scopus BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Scopus BioPharma has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Summary

Scopus BioPharma and Aditxt tied by winning 5 of the 10 factors compared between the two stocks.

How does Scopus BioPharma compare to Vaxxinity?

Scopus BioPharma (NASDAQ:SCPS) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Vaxxinity had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Vaxxinity and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Vaxxinity Neutral

82.9% of Vaxxinity shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Vaxxinity N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Scopus BioPharma has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, meaning that its share price is 7,537% less volatile than the broader market.

Summary

Vaxxinity beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Eloxx Pharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Eloxx Pharmaceuticals Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Eloxx Pharmaceuticals N/A N/A N/A

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1907.33, indicating that its stock price is 190,833% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

22.6% of Orgenesis shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Orgenesis has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Scopus BioPharma Neutral

Scopus BioPharma has lower revenue, but higher earnings than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K4.61-$55.36M-$11.51N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Scopus BioPharma N/A N/A N/A

Summary

Scopus BioPharma beats Orgenesis on 4 of the 7 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E RatioN/A1.4621.2225.66
Price / SalesN/A119.63562.2886.31
Price / CashN/A20.0743.4956.67
Price / BookN/A7.5910.317.14
Net Income-$11.61M-$3.64M$3.57B$335.98M
7 Day PerformanceN/A3.01%6.43%4.15%
1 Month PerformanceN/A76.62%3.57%2.54%
1 Year PerformanceN/A126.61%34.07%35.06%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
VINC
Vincerx Pharma
N/A$0.02
+31.8%		N/A-73.9%$89KN/AN/A60
ADTX
Aditxt
0.8026 of 5 stars		$0.07
-20.7%		N/A-100.0%$80KN/AN/A60
VAXX
Vaxxinity
N/A$0.00
flat		N/A+0.0%$13KN/AN/A90
ELOX
Eloxx Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel